Targeted pathways
Research centered on chemokine and chemoattractant receptors involved in directing immune-cell activity.
An independent overview of ChemoCentryx’s scientific history and its work in research focused on inflammatory and autoimmune conditions.
ChemoCentryx historically focused on chemoattractant pathways and small-molecule medicines being investigated for serious diseases.
Research centered on chemokine and chemoattractant receptors involved in directing immune-cell activity.
The company’s historical research included inflammatory and autoimmune disorders, including rare diseases.
Its development work included orally administered small-molecule therapeutic candidates.
ChemoCentryx was a biopharmaceutical company founded in 1997. Its research and development activities focused on medicines for inflammatory diseases, autoimmune conditions and cancer.
Amgen completed its acquisition of ChemoCentryx in October 2022. This page is an independent educational overview and is not maintained by either company.
Use these external sources for authoritative company and historical information.